HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptorantagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
The conversation discusses Perez Hilton's hair loss despite having three hair transplants. Participants suggest that hair loss can continue after a transplant if maintenance treatments like finasteride and minoxidil are not used, and that transplanted hair can still be susceptible to loss.
NMN shows promise in promoting hair growth by reducing oxidative stress and weakening androgens. It may be a beneficial addition to hair loss treatments like Minoxidil and Finasteride.